33469-13-5

Usage

Uses

Used in Organic Synthesis:
1H-Imidazole, 2-(2-chlorophenyl)-5-(trifluoromethyl)is used as a building block in organic synthesis for the creation of various pharmaceuticals and agrochemicals. Its unique structure allows for the development of new compounds with specific properties and applications.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 1H-Imidazole, 2-(2-chlorophenyl)-5-(trifluoromethyl)serves as a key intermediate in the synthesis of drugs. Its presence in the molecular structure can impart specific therapeutic effects, making it valuable in the development of new medications.
Used in Coordination Chemistry:
1H-Imidazole, 2-(2-chlorophenyl)-5-(trifluoromethyl)can act as a ligand in coordination chemistry. Its ability to form complexes with metal ions allows for the exploration of new materials with unique properties, such as catalysts, sensors, and materials with specific electronic or magnetic characteristics.
Used as a Precursor in Chemical Production:
1H-IMidazole, 2-(2-chlorophenyl)-5-(trifluoroMethyl)also serves as a precursor in the production of various other chemical compounds. Its versatile structure enables the synthesis of a wide range of products, contributing to the advancement of the chemical industry.
Used in Medicinal Research:
Due to its potential biological activity, 1H-Imidazole, 2-(2-chlorophenyl)-5-(trifluoromethyl)may be utilized in medicinal research. Its unique properties could lead to the discovery of new therapeutic agents or contribute to a better understanding of biological processes.

Upstream product

• 89-98-5 2-chloro-benzaldehyde 
• 431-67-4 1,1-dibromo-3,3,3-trifluoroacetone 
• 91944-47-7 3,3,3-Trifluoropyruvaldehyde 

Downstream Products

• 279250-96-3 2-(2-chlorophenyl)-4-cyano-1H-imidazole 
• 279251-14-8 2-(2-chlorophenyl)-1H-4-imidazolcarbaldehyde 

Relevant academic research and scientific papers

Liver X Receptor (LXR) partial agonists: Biaryl pyrazoles and imidazoles displaying a preference for LXRβ

A series of biaryl pyrazole and imidazole Liver X Receptor (LXR) partial agonists has been synthesized displaying LXRβ selectivity. The LXRβ selective partial agonist 18 was identified with potent induction of ATP binding transporters ABCA1 and ABCG1 in human whole blood (EC50 = 1.2 μM, 55% efficacy). In mice 18 displayed peripheral induction of ABCA1 at 3 and 10 mpk doses with no significant elevation of plasma or hepatic triglycerides at these doses, showing an improved profile compared to a full pan-agonist.

Synthesis, structure, and neuroprotective properties of novel imidazolyl nitrones

A new series of imidazolyl nitrones spin traps has been synthesized and evaluated pharmacologically. The salient structural feature of these molecules is the presence of an imidazole moiety substituted by aromatic or heteroaromatic cycles. This connectivi

Trifluoromethylimidazoles and a method for their preparation

4(5)-Trifluoromethylimidazoles having optional substituents in the 1 and 2 positions are provided. The novel 4(5)-trifluoromethylimidazoles are prepared by reacting a 1,1-dihalo-3,3,3-trifluoroacetone compound with an appropriate carboxaldehyde and ammoni

2-Pyrazinyl-trifluoromethylimidazoles and a method for their preparation

4(5)-Trifluoromethylimidazoles having optional substituents in the 1 and 2 positions are provided. The novel 4(5)-trifluoromethylimidazoles are prepared by reacting a 1,1-dihalo-3,3,3-trifluoroacetone compound with an appropriate carboxaldehyde and ammoni

4-Trifluoromethylimidazoles and 5-(4-pyridyl)-1,2,4-triazoles, new classes of xanthine oxidase inhibitors.

The syntheses of a number of 2-substituted 4-trifluoromethylimidazoles and 3-substituted 5-(4-pyridyl)-1,2,4-triazoles are described. The trifluoromethylimidazoles were prepared from 3,3-dibromo-1,1,1-trifluoroacetone after hydrolysis with aqueous sodium acetate solution and condensation with an aldehyde in the presence of ammonia. Basic hydrolysis of the trifluoromethyl group was found to provide a facile method for the synthesis of imidazole-4-carboxylic acids. In the imidazole series a 2-aryl substituent and a free imino group were required for xanthine oxidase inhibitory activity. The triazoles were obtained through the reaction of an aroylhydrazine and an imino ether followed by thermal ring closure of the intermediate acylamidrazone. As in the imidazole series, a free imino group is an absolute requirement for in vitro activity. Additional structure-activity relationships of these compounds are presented.